Clinical Trial Update: Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating bevacizumab for renal cell carcinoma has completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Renal Cell Carcinoma, Kidney Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-01-14